AN2 Therapeutics initiated with an Outperform at JMP Securities

JMP Securities initiated coverage of AN2 Therapeutics with an Outperform rating and $30 price target. The company’s lead candidate epetraborole is a potent, rationally-designed antibiotic in Phase 2/3 for mycobacterium avium complex lung disease, and it could be the first FDA-approved oral option for the indication, the analyst tells investors in a research note. The firm says MAC NTM is an important indication and opportunity.